# An Exploratory Clinical Trial Evaluating the Tolerability and Efficacy of KH906 in Patients With Corneal Neovascularization

> **NCT04215393** · PHASE1 · UNKNOWN · sponsor: **Chengdu Kanghong Biotech Co., Ltd.** · enrollment: 39 (estimated)

## Conditions studied

- Corneal Neovascularization

## Interventions

- **DRUG:** Conbercept eye drop
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04215393
- **Lead sponsor:** Chengdu Kanghong Biotech Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-07-18
- **Primary completion:** 2020-04
- **Final completion:** 2020-12
- **Target enrollment:** 39 (ESTIMATED)
- **Last updated:** 2020-01-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04215393

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04215393, "An Exploratory Clinical Trial Evaluating the Tolerability and Efficacy of KH906 in Patients With Corneal Neovascularization". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04215393. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*